Please login to the form below

Not currently logged in
Email:
Password:

Zelluna appoints Miguel Forte as CEO

He joins the Norwegian biotech from Bone Therapeutics

Miguel ForteZelluna Therapeutics has appointed its new chief executive officer in the form of Miguel Forte.

His new role will see him lead Zelluna through its next stage of development by driving clinical translation of the TCR pipeline, developing new international scientific and commercial partnerships and forging relationships with the international investor communities.

Forte said: “Zelluna has a very strong foundation, based on over 30 years of cutting edge research.

“I wished to join Zelluna to combine my experience to the considerable potential of Zelluna to position is as an international immunotherapy leader and bringing serious therapeutic options to patients of the most common and fatal solid cancers.”

Prior to his new role, Forte has held roles for Bone Therapeutics, TxCell, the European Medicines Agency, Bristol-Myers Squibb, Abbott, and UCB to name a few.

Forte’s expertise is predominantly in regenerative medicine, cell therapy, medical and regulatory affairs industries and is currently chief commercialisation officer and chair of the commercialisation committee for the International Society of Cellular Therapy.

Anders Tuv, chairman of the board, Zelluna, said: “Appointing a CEO with the international experience and profile of Miguel Forte will be critical to further enhance the therapeutic development and commercial potential of Zelluna, and push its leadership position in the international TCR and immunotherapy marketplaces.”

14th November 2017

From: Sales

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Nucleus Global

Nucleus Global is the largest specialist medical communications network in the world. Globally, we have over 800 experts delivering world-class...

Latest intelligence

Diversity in clinical trials: looking back at our 2021 blogs
In this blog, we look back at the Innovative Trials' Equality & Diversity (E&D) committee blogs across 2021...
What does the future hold for Light-chain Amyloidosis?
Recent advances in the understanding and treatment are reforming pharma’s approach to the management of this rare disease. With a new standard of care rapidly developing, what does the landscape...
Webinar:
Securing a future for telehealth with immersive market research insights...